logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Cabozantinib in combination with atezolizumab for advanced hepatocellular carcinoma –first line

< Back

Cabozantinib in combination with atezolizumab for advanced hepatocellular carcinoma –first line

Drugs

Cancer and Palliative Care

February 2021


Cabozantinib in combination with atezolizumab is in clinical development for the treatment of advanced hepatocellular carcinoma (aHCC). HCC is the most common type of liver cancer and occurs mainly in patients with underlying chronic liver disease and cirrhosis. aHCC occurs when the cancer has spread to lymph nodes or other organs and is often diagnosed late in life with poor prognosis.
Oral cabozantinib is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of enzymes known as tyrosine kinases which can be found in certain receptors in cancer cells. Intravenous atezolizumab is a monoclonal antibody, a type of protein designed to recognise and attach to a protein called PD-L1, which is present on many cancer cells. Their combination has shown promising antitumour activity and tolerability in patients with solid tumours including HCC. If licensed, cabozantinib in combination with atezolizumab will provide an additional first-line treatment option for patients with advanced HCC.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts